Editas Medicine Inc.

Editas Medicine Inc. (NASDAQ: EDIT) is a gene-editing company that is developing treatments for patients with genetically defined diseases. The company's proprietary genome editing platform is based on CRISPR/Cas9 technology, which is a powerful tool that can be used to edit DNA. Editas Medicine is currently developing several CRISPR-based treatments for diseases such as sickle cell disease, beta thalassemia, and Usher syndrome.

Recent Financial and Business Updates:

• Second Quarter Income Statement Review:
  • Editas Medicine's net loss attributable to common stockholders was USD40.3 million, or USD0.56 per share. This represents an improvement from the net loss of USD53.5 million, or USD0.78 per share, in the same period of 2022.
  • The collaboration and other research and development revenue decreased by USD3.5 million to USD2.9 million in Q2 2023, compared to USD6.4 million in the same period of 2022. This is because Bristol Myers Squibb did not opt-in to the program in Q2 2023, unlike in the same period of 2022.
  • Its research and development expenses decreased by USD13.9 million, from USD43.7 million in the second quarter of 2022 to USD29.8 million in the second quarter of 2023. This is due to the company's strategic reprioritization, which includes a focus on EDIT-301, a gene-editing treatment for sickle cell disease, and reduced employee-related costs.
  • General and administrative expenses remained relatively flat, increasing by USD0.3 million to USD17.2 million in the second quarter of 2023 from USD16.9 million in Q2 of 2022.
• Balance Sheet Review:
  • The company’s cash, cash equivalents, and marketable securities increased by USD78.2 million from USD401.8 million as of March 31, 2023, to USD480.0 million as of June 30, 2023.
  • Its total assets stood at USD 541.95 million as on June 30, 2023.
  • EDIT’s total liabilities stood at USD 142.036 million.
  • The company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditures into the third quarter of 2025.

Technical Observation (on the daily chart)

Presently, the stock has given a return of approximately 33.55% since reaching its lowest point in the past 52 weeks, which occurred on April 12, 2023. The Relative Strength Index (RSI) over a 14-day period stands at 41.34. Moreover, the price is currently positioned below both the 21-day SMA and 50-day SMA trend-following indicators, which may act as dynamic short-term resistance levels.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a “WATCH” rating is recommended for Editas Medicine Inc. (NASDAQ: EDIT) at its current price of USD8.44 on September 14, 2023, at 08:15 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario.

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing. 

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

How to Read the Charts?

The yellow colour line reflects the 21-period simple moving average (SMA) while the blue line indicates the 50- period simple moving average (SMA). SMA helps to identify existing price trends. If the prices are trading above the 21-period and 50-period moving average, then it shows prices are currently trading in a bullish trend.

The orange colour line in the chart’s lower segment reflects the Relative Strength Index (14-Period) which indicates price momentum and signals momentum in trend. A reading of 70 or above suggests overbought status while a reading of 30 or below suggests an oversold status.

The red and green colour bars in the chart’s lower segment show the volume of the stock. The volume is the number of shares that changed hands during a given day. Stocks with high volumes are more liquid than stocks with lesser volume as liquidity in stocks helps with easier and faster execution of the order.

The Orange colour lines are the trend lines drawn by connecting two or more price points and used for trend identification purposes. The trend line also acts as a line of support and resistance.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock. 

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock. 

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices. 

The reference date for all price data, currency, technical indicators, support, and resistance levels is September 14, 2023. The reference data in this report has been partly sourced from REFINITIV. 

Abbreviations

CMP: Current Market Price

SMA: Simple Moving Average

RSI: Relative Strength Index

USD: United States dollar 

Note: Trading decisions require a thorough analysis by individual. Technical reports in general chart out metrics that may be assessed by individuals before any stock evaluation. The above are illustrative analytical factors used for evaluating the stocks; other parameters can be looked at along with additional risks per se. Past performance is neither an indicator nor a guarantee of future performance.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services. Please note past performance is neither an indicator nor a guarantee of future performance.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.